#41

CARPE_DIEM results: Rapamycin and Alzheimer Disease: a Hypothesis for the Effective use of Rapamycin - #6 by RapAdmin

Tl;dr: 1 mg/day of rapa for 8 weeks did not get into the CSF and some biomarkers were worse after treatment.

#42

Let us recall again this study from 2023, where sirolimus and tacrolimus had differential impact based on peripheral vs CNS penetration:

Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine

"Results:

All drugs examined reduced dementia prevalence compared to the general population-like control. There were no differences in dementia diagnoses upon comparing tacrolimus and sirolimus; however, patients prescribed tacrolimus had a reduced dementia prevalence relative to cyclosporine.

Conclusion:

Converging mechanisms of action between tacrolimus and sirolimus likely explain the similar dementia prevalence between the cohorts. Calcineurin inhibition within the brain has a greater probability of reducing dementia relative to peripherally-restricted calcineurin inhibition. Overall, immunosuppressants provide a promising therapeutic avenue for dementia, with emphasis on the brain-penetrant CNI tacrolimus."